Sleep disturbance is a common feature during mood episodes in bipolar disorder. The aim of this study was to investigate the prevalence of such symptoms among euthymic bipolar patients, and their association with risk for mood episode recurrence. A cohort of bipolar I and II subjects participating in the Systematic Treatment Enhancement Program for Bipolar Disorder who were euthymic for at least 8 weeks were included in this analysis. Survival analysis was used to examine the association between sleep disturbance on the Montgomery-Asberg Depression Rating Scale (MADRS) and recurrence risk. A total of 73/483 bipolar I and II subjects reported at least mild sleep disturbance (MADRS sleep item 2) for the week prior to study entry. The presence of sleep problems was associated with a history of psychosis, number of previous suicide attempts, and anticonvulsant use. Sleep disturbance at study entry was significantly associated with risk for mood episode recurrence. Sleep disturbance is not uncommon between episodes for individuals with bipolar disorder and may be associated with a more severe course of illness. This suggests that sleep disturbance is an important prodromal symptom of bipolar disorder and should be considered a target for pharmacologic or psychosocial maintenance treatment.
Introduction
Sleep disturbance is common among bipolar patients (Harvey, 2008) and substantially impacts quality of life (Giglio et al., 2009; Gruber et al., 2009 ) by negatively affecting the course and prognosis of the disorder. Disruptions in sleep often occur before the onset of a mood episode, and are also common symptoms of acute bipolar episodes (Bauer et al., 2006; Harvey, 2008; Harvey et al., 2005; Jackson et al., 2003) . These disruptions are a marker of inadequate recovery from a mood episode (Harvey, 2008) and are often associated with comorbid conditions, such as anxiety (Harvey et al., 2005) . Artificially disrupting sleep (i.e. with behavioral manipulations) in bipolar disorder can cause mania or hypomania (for a review, see Wu and Bunney (1990) ), and in depressed bipolar patients, clinically induced sleep deprivation has an antidepressant effect (Wehr et al., 1987; Wu and Bunney, 1990) . Sleep disturbance may also be a defining feature of the disorder in all phases of illness, given that sleep may be problematic even in euthymic bipolar patients (Harvey et al., 2005; Plante and Winkelman, 2008) . Individuals with bipolar disorder may have a biological vulnerability to dysregulated sleep due to having a genetic abnormality in their circadian rhythm system (Ehlers et al., 1988; Grandin et al., 2006; Harvey et al., 2005; Murray and Harvey, 2010; Wehr et al., 1987) .
In the current study, we examined euthymic bipolar patients to investigate the prevalence of residual sleep disturbance and its potential association with risk for a subsequent mood episode. Given that comorbid diagnoses, such as anxiety, can exacerbate sleep disturbance in individuals with bipolar disorder and that medications can alter sleep (Harvey et al., 2005) , we also examined whether these variables affect the time to mood recurrence after a mood episode. The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), a multicenter effectiveness study, afforded an opportunity to study the impact of sleep disturbance in a large and generalizable cohort of well-characterized, clinically representative bipolar I and II participants.
Methods

Study overview
STEP-BD was a multicenter study designed to evaluate longitudinal outcomes in individuals with bipolar disorder. All participants received standardized prospective evaluation, including structured and semi-structured assessments and clinical interviews (Sachs et al., 2003) . Subjects were recruited between 1999 and 2005. The human research committees of all 16 participating sites approved the STEP-BD protocol. Participants in the Standard Care Pathway of STEP-BD could receive any clinically indicated intervention. Study psychiatrists were trained to utilize model practice procedures, including evidence-based pharmacology (Sachs et al., 2003) .
Participants
Eligibility in STEP-BD required that participants were at least 15 years of age and met DSM-IV criteria for bipolar I disorder, bipolar II disorder, cyclothymia, bipolar disorder not otherwise specified (NOS), or schizoaffective disorder, bipolar subtype. STEP-BD exclusion criteria included unwillingness or inability to give informed consent or comply with study assessments. Subjects in the present study were a set of 483 individuals with bipolar I or II disorder drawn from the STEP-BD cohort who were euthymic, as defined by Young Mania Rating Scale score 12, Montgomery-Asberg Depression Rating Scale (MADRS) score 10, and a clinical status of 'in recovery' for at least 8 weeks.
Assessments
Treating psychiatrists in STEP-BD were trained in the empirically supported guidelines for the treatment of bipolar disorder (Suppes et al., 2005) , including use of standardized evaluation tools and rating scales. All methods and assessments used in STEP-BD have been described elsewhere (Sachs et al., 2003) .
The Affective Disorder Evaluation (ADE) (Sachs et al., 2003) utilizes adaptations of the mood and psychosis modules from the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (American Psychiatric Association, 1994) Axis I Disorders, Patient Edition (SCID-P) (First et al., 1996) . It was administered to all participants at study entry, and was the primary means of establishing diagnosis. The ADE also included systematic assessment of lifetime and recent course of illness based on patient report.
The Mini International Neuropsychiatric Interview (MINI Version 4.4) (Sheehan et al., 1998) was used to confirm bipolar diagnosis and establish comorbid axis I diagnoses. The MINI is a brief structured interview designed to identify the major Axis I psychiatric disorders in the DSM-IV and the tenth revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) (World Health Organization, 1992) . The MINI and ADE were completed by different study clinicians, and a consensus diagnosis of one of the eligible bipolar disorders was required on both the ADE and MINI for study entry. The Young Mania Rating Scale (YMRS) (Young et al., 1978) , an 11-item, clinician-administered assessment of manic symptoms, and the MADRS (Montgomery and Å sberg, 1979), a 10-item, clinician-administered assessment of depressive symptoms, were administered at each follow-up visit to determine current severity of symptoms (Sachs et al., 2003) .
The Clinical Monitoring Form (CMF) (Sachs et al., 2003 ) was used to collect DSM-IV criteria for depressive, manic, hypomanic, or mixed states and was administered at each follow-up visit to determine clinical status.
Study outcomes
Independent study assessments were conducted at fixed intervals, and clinical status was assessed at each follow-up visit with the CMF. Remission was defined as two or fewer syndromal features of mania, hypomania, or depression for at least 8 weeks. Recurrence was defined as meeting full DSM-IV criteria for a manic, hypomanic, mixed, or depressive episode on any one follow-up visit. Occurrence of subsyndromal mood symptoms during follow-up was not considered recurrence.
MADRS item 4 ('reduced sleep') measures the subject's rating of reduced duration or depth of sleep compared to the subject's normal sleep pattern, and was used as the primary measure of 'sleep disturbance' in the present study. Consistent with previous literature, the definition of 'sleep disturbance' is a score of 2 or greater on MADRS item (Williamson et al., 2006) . While the MADRS is not specifically a sleep measure, individual items are considered to be reliable and valid (Montgomery and Å sberg, 1979; Welmer et al., 2007) .
Statistical analysis
After confirmation that distribution assumptions were met, parametric univariate tests for association (i.e. Student's t-tests), or chi-squared tests, were used to examine the relationship between baseline sociodemographic, clinical features, and sleep disturbance. We used survival analysis to examine time from study entry to first manic, hypomanic, mixed, or major depressive episode. Data was censored after completion of 2 years of follow-up or last recorded visit. Cox regression was utilized after confirmation that the proportional hazards assumption was met by incorporating a variable-by-time term in regression models, and by visual inspection of hazard plots. Baseline sociodemographic and clinical variables (Table 1) were examined as potential confounders by incorporating them individually into a Cox regression model to investigate whether resulting hazard ratios for the sleep disturbance term changed by 10% or more. This strategy is often used in other studies (Tong and Lu, 2000) and is suggested as a means of determining confounding variables (Bliss et al., 2011; Kleinbaum and Klein, 2010) . All analyses were conducted using Stata 10.0 (College Station, TX).
Results
In this cohort, 73/483 (15%) of euthymic participants reported at least mild sleep disturbance. The presence of sleep disturbance was not associated with gender, age, race, marital status, bipolar subtype, rapid cycling in the prior year, or comorbid axis I anxiety or substance abuse disorder (Table  1) . Sleep disturbance was less prevalent in individuals with a history of psychosis, but more prevalent in those with a history of suicide attempts and (hypo)manic symptoms ( p < 0.05) (see Table 1 ).
There was no association of sleep disturbance with pharmacotherapy, defined as use of lithium, valproate, atypical antipsychotics, or lamotrigine (see Table 2 ). However, there was a significant association with use of other anticonvulsants; individuals taking these medications were significantly more likely to have sleep disturbance ( p < 0.05).
In the survival analysis, we found that the presence of sleep disturbance was significantly associated with a greater risk for mood episode recurrence (Kaplan-Meier log rank p < 0.05; see Figure 1 ). In Cox regression, incorporating terms for sociodemographic and clinical features examined in Table 1 did not change the hazard ratio by 10% or more, suggesting that they do not confound the association between residual sleep disturbance and recurrence risk.
For exploratory purposes, we also examined time to recurrence by pole separately for depressive episode and manic/ hypomanic/mixed episodes recurrence, with results censored at any recurrence (i.e. if a subject initially relapsed or recurred into mania, subsequent observations for that subject were censored and not further considered in analysis of time to depression). We found numerically increased risk for recurrence to both poles, for depression the hazard ratio was 1.45 (95% CI 0.88-2.40; p ¼ 0.14) and for mania/hypomania/mixed state, the hazard ratio was 1.79 (95% CI 0.92-3.4449; p ¼ 0.09).
Discussion
We found that residual sleep disturbance among euthymic bipolar I and II patients was associated with the risk of recurrence of subsequent mood episodes. Sleep disturbance was also associated with a history of psychosis, number of previous suicide attempts, and the use of anticonvulsants, but not with other medications.
This study supports previous findings that bipolar patients experience sleep disturbance even during euthymic periods (e.g. Plante and Winkelman, 2008) . Giglio and colleagues, in a cross-sectional study, found that euthymic bipolar patients with sleep disturbance had worse quality of life and more impairment in social and environmental domains, than those without sleep disturbance (Giglio et al., 2009) . These data could suggest that sleep disturbance may be both a symptom of the disorder, and a significant trigger for acute episodes as evidenced by our exploratory analyses showing a trend for sleep to be more disruptive during bipolar episodes. That sleep disturbance occurs in the absence of a mood episode, and is not associated with most medications, suggests that sleep disturbance and bipolar disorder may share a similar etiology or overlapping pathophysiology (Grandin et al., 2006; Harvey et al., 2005) . This possibility is supported by studies that have found sleep disturbance is worse in euthymic bipolar patients than in matched normal controls (Knowles et al., 1986; Millar et al., 2004) .
Although the underlying mechanisms have yet to be elucidated, this study demonstrates that residual sleep disturbance is a primary prodromal symptom of bipolar episodes. Given that relapse rates are high in bipolar disorder (Gitlin et al., 1995) and that identification and treatment of prodromal symptoms are crucial for relapse prevention (Otto and Reilly-Harrington, 2002) , sleep maintenance is an important treatment goal. We also found that sleep disturbance is associated with (hypo)manic symptoms which has been well documented in the literature (Wehr, 1991; Wehr et al., 1987) , further highlighting the need to assess sleep problems during euthymic periods for individuals with bipolar disorder. Thus, clinicians should be mindful to assess carefully for sleep disturbance, even in the absence of other bipolar symptoms. Interestingly, we did not find that sleep disturbance was associated with depressive symptoms during euthymic periods. There is some evidence that extreme sleep disturbance, or total sleep deprivation, has antidepressant features (Benedetti et al., 2003; Giedke and Schwa¨rzler, 2002) but triggers mania (Wehr, 1992 ). Yet, the lack of association between sleep disturbance and depressive symptoms is an unusual finding and warrants further research. Sleep disturbance, among euthymic bipolar individuals, is associated with a history of suicide attempts; often an indicator of severe affect dysregulation. For example, other studies have found that sleep disturbance is associated with increased impulsivity (Dahl et al., 1996; Harvey et al., 2005) . In nonclinical populations, sleep loss has been shown to intensify negative emotions as well as to diminish positive emotions (Zohar et al., 2005) . Thus, managing sleep may improve both affect regulation and impulsivity.
Finally, any discussion of sleep disturbance must consider the use of medications which can alter sleep architecture. In our study, we found that subjects with a history of psychosis were less likely to report sleep disturbance. This may be associated with the use of atypical antipsychotic medications in this population, although sleep disturbance was not more prevalent among patients taking atypical antipsychotics. Sleep disturbance was significantly associated with use of 'other' anticonvulsants, although the vast majority of subjects in this category were taking gabapentin, likely reflecting the use of this medication specifically for insomnia.
This study provides prospective data from a large, generalizable outpatient sample of well-characterized euthymic bipolar I and II patients who were treated in a naturalistic setting; however, we lacked a comprehensive characterization of sleep using a validated scale, such as the Pittsburgh Sleep Quality Index (Backhaus et al., 2002) . The MADRS, while a valid scale of depressive symptoms, is not specifically a sleep scale and includes only one sleep item. Given that the MADRS sleep item assesses 'reduced sleep', it does not capture sleep disturbance due to increases in sleep, or over sleeping. This item also does not capture the causality of sleep disturbance, for example, individuals may experience a decreased need for sleep due to hypomania/mania. This is important to note as hypomania symptoms were associated with dysregulated sleep (see Table 1 ). The MADRS is also based largely on patient self-report, which can be unreliable; however, other studies have used this item to define sleep problems (Lader et al., 2005; Williamson et al., 2006) . In future investigations, the assessments of sleep disturbance with more objective measures, such as polysomnography or actigraphy, would be valuable.
Conclusion
Sleep disturbance is common among euthymic bipolar patients and is an independent risk factor for recurrent mood episodes. Thus, maintenance treatment for bipolar disorder should include careful assessment and management of sleep disturbance. 
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